Cervomed Inc. · NASDAQ:CRVO
Cervomed — Diffusion Pharmaceuticals — Canaccord Growth Conference 2023
20 slides from Cervomed's conference presentation, Aug 9, 2023
Slide 1: Canaccord Growth Conference Investor Presentation
PHARMA Canaccord Growth Conference Aug 9-10, 2023; Boston nvestor Presentation
Slide 2: No Offer or Solicitation
No Offer o Solicitation ‘This communication shall nt constitute an offer to sell or the solicitation ofan oer to buy any secures, nor shall there be any sale of secur in any jurslction in which such offer, saltaion ef sale would Be uniawful prior to registration or qualification under the secutties
Slide 3: Forward-Looking Statements
Forward-Looking Statements ‘This presentation includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1996, as amended, regarding management's intentions, plans, beliefs, expectations or forecasts for the future, including, but no
Slide 4: Planned Merger
Planned Merger’ E | Pp Diffus Pharmaceuticals inc. Diffusion sharehelders expected to vn 24.68% ofthe total hhumber of eutstancing 3 shares of eapial stock of Newco? BoE eee nine $ CERVOMED + Phase 2b clinical asset "Medicines for the Brait Merger expected to close + Expected cash runway through Pha
Slide 5: EIP Pharma at a Glance
EIP Pharma at a Glance E | Pp Late Clinical Stage CNS Company PHARMA Differentiated approach to age-related neurologic disorders with a late-stage lead clinical asset; pipeline of additional indications and second asset Phase 2b Ready Lead Drug Candidate Neflamapimod has the potential to be the firs
Slide 6: EIP Pharma Pipeline
EIP Pharma Pipeline @EIP IP Conan: PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEFLAMAPIMOD 7 : Circulation Ischemic Stroke Disease (EOAD) Mw EIP200 (novel co-crystal) Multiple CNS ww *Received FDA Fast Track designation
Slide 7: Opportunity for Therapeutics Targeting Basal Forebrain Cholinergic Degeneration
Opportunity for Therapeutics Targeting Basal Forebrain Cholinergic Degeneration + Age-related degeneration of the basal forebrain cholinergic system plays major role in many neurologic disorders: + Dementia with Lewy bodies (DLB), where it is the primary pathology + Early stages of Alzheimer's + Imp
Slide 8: Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies (DLB) What is DLB? + Disease associated with abnormal deposits of a protein called alpha- ‘synuclein in the brain, These deposits, called Lewy bodies, affect chemicals inthe brain whose changes, in tum, can lead to problems with thinking, movement, behavior, and mood + Pati
Slide 9: Neflamapimod Overview
Neflamapimod Overview E | Pp Mechanism Toxicology Clinical Safety Clinical Efficacy PHARMA Through specifically inhibiting p38a kinase treats synaptic dysfunction Reverses neurodegenerative process in the basal forebrain in preclinical studies ‘Completed long-term toxicology studies in two species ‘
Slide 10: Neflamapimod Reverses Cholinergic Dysfunction and Degeneration
Neflamapimod Reverses Cholinergic Dysfunction and Degeneration Ts2 mice Down Syndrome transgenic mouse model Develop adult-onset basal forebrain cholinergic degeneration Treated with vehicle or 3 mg/kg NFMD BID x 28 days Reversed basal forebrain cholinergic neuron loss and restored cholinergic funct
Slide 11: Phase 2a Exploratory Clinical Study in Dementia with Lewy Bodies
Phase 2a Exploratory Clinical Study in E | Pp Dementia with Lewy Bodies (DLB) PHARMA GscenD-LB Outcome Measures Patients + DLB specific Neuropsychological Test Battery (NTB, a cognitive test battery) Dementia Severity, assessed by COR-SB. Motor Function, assessed by Timed Up and Go (TUG) test + Mild
Slide 12: AscenD-LB demonstrated neflamapimod significantly improved cognition and function
AscenD-LB demonstrated neflamapimod significantly improved cognition and function in mild-to-moderate DLB GscenD-LB 40mg BID + 40mg TID 40mg TID Mean vs. Mean vs. ‘Outcome Measure placebo p-value placebo p-value (95% Cl) (95% cl) Dementia Clinical Dementia Rating 0.45 0.023 C+] 0.56 0.007 [+] Severi
Slide 13: Biomarker Results Support Enrichment Strategy for Future Trials
Biomarker Results Support Enrichment Strategy for Future Trials * 35-50% of patients with DLB have biomarker evidence of Alzheimer’s disease (AD) + Represent patients with extensive neurodegeneration (neuronal loss) in the cerebral cortex, particularly in the medial temporal lobe (j.e., in the hippo
Slide 14: Phase 2b Confirmatory Study in DLB
Phase 2b Confirmatory Study in DLB FIP RewinD-LB Patients DLB by consensus criteria (MeKeith, Neurology, 2017) Outcome Measures + 1°: COR-Sum of Boxes + 2: Cognition assessed by DLB-specific : Neuropsychological Test Abnormal dopamine — ch Battery (NTB), CGIC; Motor uptake by DaTscan™ Lede te te dy
Slide 15: Neflamapimod for DLB: Well-Positioned
Neflamapimod for DLB: Well-Positioned Commercially Significant Patient Numbers Specialist Disease: Growth in Diagnosis Rates: ing s Diagnosed and managed srologi High Medical Need / Builds on Existing Pricing Leverage: Treatment Paradigm: ve to AD: fate of cognition Choli inhibitors. utilized
Slide 16: Key Individuals
Key Individuals Management John Alam, MD President, CEO & Co-Founder Executive Chair & Co-Founder 3 9° & Kelly Blackburn ‘SVP, Clinical Development Ferman cin atare o yPar VP, Ce * frtiinsverornpets one Vaca formate mye EIP PHARMA Sylvie Gregoire, PharmD (Chair) Jeff Poulton (Chair of Audit Committe
Slide 17: Key Upcoming Anticipated Milestones/Catalysts
Key Upcoming Anticipated E | Pp Milestones/Catalysts PHARMA vy NlA approves $21M grant for Q Publish additional Phase 2a Q_ Complete enrollment in Phase Phase 2b data’ from DLB study 2b DLB study (1H) ¥ Signed merger agreement Q FPD in Phase 2b DLB study Report data from placebo- with Diffusion Phar
Slide 18: Summary
Summary E | Pp PHARMA @ Differentiated Approach to Age-related Neurologic Disorders with a Late-Stage Asset Major value creation potential in phase 2b read-out in dementia with Lewy bodies Experienced Management Team and Board of Directors Potential to broaden opportunity through additional indicati
Slide 19: CervoMed: Medicines for the Brain
EIP PHARMA CERVOMED “Medicines for the Brain” le cerveau (sair-voh), noun, masculine in French for brain or mind
Slide 20: Canaccord Growth Conference Investor Presentation
2 PHARMA Canaccord Growth Conference Aug 9-10, 2023; Boston Invest 1
Diffusion Pharmaceuticals — Canaccord Growth Conference 2023 on 6ix